United States · FDA National Drug Code directory
QELBREE
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 17772-133_5b89031c-41a3-d7e0-e063-6294a90af6fb
- Product NDC
- 17772-133
- Form
- CAPSULE, EXTENDED RELEASE
- Composition / generic term
- viloxazine hydrochloride
- Labeler
- Supernus Pharmaceuticals, Inc
- Marketing category
- NDA
- Marketing start / end (source format)
- 20210402
- Source listing expiry
- 20271231
Source-listed ingredients
- VILOXAZINE HYDROCHLORIDE — 200 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-133-01) · 17772-133-01
- 7 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-133-07) · 17772-133-07
- 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-133-30) · 17772-133-30
- 60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-133-60) · 17772-133-60
- 90 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-133-90) · 17772-133-90
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →